Search results for "antibiotic"

showing 10 items of 807 documents

Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infecti…

2018

ESGAP, ESGBIS, ESGIE and the CRGNB treatment survey study group.

0301 basic medicineAcinetobacter baumanniiCarbapenemAntibioticsDrug ResistanceDrug resistanceTigecyclineAcinetobacter baumannii; Carbapenem; Carbapenem-resistant Gram-negative bacilli; Combination therapy; Enterobacteriaceae; Polymyxin; Pseudomonas aeruginosa; SurveyPolymyxin0302 clinical medicineSurveys and Questionnairespolycyclic compounds030212 general & internal medicineAcinetobacter baumannii; Carbapenem; Carbapenem-resistant Gram-negative bacilli; Combination therapy; Enterobacteriaceae; Polymyxin; Pseudomonas aeruginosa; Survey; Anti-Bacterial Agents; Carbapenems; Cross Infection; Cross-Sectional Studies; Drug Resistance Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Microbial Sensitivity Tests; Surveys and QuestionnairesSurveyCarbapenemAcinetobacter baumannii; Carbapenem; Carbapenem-resistant Gram-negative bacilli; Combination therapy; Enterobacteriaceae; Polymyxin; Pseudomonas aeruginosa; Survey; Anti-Bacterial Agents; Carbapenems; Cross Infection; Cross-Sectional Studies; Drug Resistance Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Microbial Sensitivity Tests; Surveys and Questionnaires; Microbiology (medical); Infectious DiseasesCross InfectionbiologyMicrobial Sensitivity TestCarbapenem-resistant Gram-negative bacilliBacterialantibiotic management carbapenem-resistant Gram-negative bacteriaGeneral MedicineHospitals3. Good healthAcinetobacter baumanniiAnti-Bacterial AgentsInfectious DiseasesPseudomonas aeruginosamedicine.drugHumanMicrobiology (medical)medicine.medical_specialtymedicine.drug_class030106 microbiologyMicrobial Sensitivity TestsFosfomycincarbapenem-resistant Gram-negative bacteria03 medical and health sciencesHospitalEnterobacteriaceaeInternal medicineAnti-Bacterial AgentDrug Resistance BacterialGram-Negative BacteriamedicineGram-Negative Bacterial InfectionHumansCombination therapyCross-Sectional Studiebusiness.industrybiochemical phenomena metabolism and nutritionbiology.organism_classificationbacterial infections and mycosesCross-Sectional StudiesCarbapenemsInfectious disease (medical specialty)Carbapenem-resistant gram-negative bacilli[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieantibiotic managementbusinessGram-Negative Bacterial InfectionsRifampicin
researchProduct

Rifampicin treatment of Blattella germanica evidences a fecal transmission route of their gut microbiota

2018

Eukaryotes have established symbiotic relationship with microorganisms, which enables them to accomplish functions that they cannot perform alone. In the German cockroach, Blattella germanica, the obligate endosymbiont Blattabacterium coexists with a rich gut microbiota. The transmission of Blattabacterium is vertical, but little is known about how the gut microbiota colonizes newborn individuals. In this study, we treated B. germanica populations with rifampicin, a broad-spectrum antibiotic, during two generations and analyzed gut bacterial composition and the Blattabacterium load in control and rifampicin-treated populations. Rifampicin exerted a drastic effect on gut microbiota compositi…

0301 basic medicineAdultMalemedicine.drug_class030106 microbiologyAntibioticsPopulationL73 Animal diseasesGut microbiotaGut floraL70 Veterinary science and hygieneL01 Animal husbandryApplied Microbiology and BiotechnologyMicrobiologydigestive systemMicrobiology03 medical and health sciencesBlattabacteriumFecesSymbiosismedicineAnimalsHumanseducationSymbiosisFecesPhylogenyGerman cockroacheducation.field_of_studyEndosymbiontEcologybiologyObligateBlattellidaebiology.organism_classificationAntibiotic treatmentAnti-Bacterial AgentsBacterial Typing TechniquesGastrointestinal MicrobiomeInsect symbiosisRifampinFlavobacteriaceaeMicrobiota transmission
researchProduct

Observational prospective study on Lactobacillus plantarum P 17630 in the prevention of vaginal infections, during and after systemic antibiotic ther…

2018

We performed a prospective cohort parallel observational study on the use of Lactobacillus plantarum P 17630 in the prevention of vaginal infections. Eligible were women with a diagnosis of bacterial vaginosis (15 days) and documented history of recurrent vaginal infections; and/or cystitis (15 days); and/or treatment with antibiotics for bacterial respiratory tract infections during the week before the study entry. Study subjects were prescribed Lactobacillus plantarum P 17630  100.000.000 UFC one vaginal capsule per day for 6 days, then a capsule per week for 16 weeks. Eligible subjects were enrolled in two parallel cohorts: 85 women using (group A) and 39 not using (group B) Lactobacillu…

0301 basic medicineAdultmedicine.medical_specialtymedicine.drug_class030106 microbiologyAntibioticsPopulationGroup B03 medical and health sciences0302 clinical medicineInternal medicineCystitismedicineSecondary PreventionHumansProspective StudiesProspective cohort studyeducationVaginitisRespiratory Tract Infectionseducation.field_of_studybiologyGenitourinary systembusiness.industryProbioticsPreventionfood and beveragesObstetrics and GynecologyMiddle Agedmedicine.diseasebiology.organism_classification030205 complementary & alternative medicineAnti-Bacterial AgentsObservational studyFemaleBacterial vaginosisbusinessbacterial vaginosis; Lactobacillus plantarum; Prevention; Adult; Anti-Bacterial Agents; Cystitis; Female; Humans; Middle Aged; Probiotics; Prospective Studies; Respiratory Tract Infections; Secondary Prevention; Vaginitis; Lactobacillus plantarum; Obstetrics and GynecologyLactobacillus plantarumbacterial vaginosis; Lactobacillus plantarum; Preventionbacterial vaginosisLactobacillus plantarum
researchProduct

It is Time for Action in the Struggle against Antibiotic-Resistance, Let’s Start Reducing or Replacing Antibiotics in Agriculture

2016

Million people around the world are infected each year and thousands of them die from pathogens that are resistant to the treatment by any of known antibiotics [1]. The excessive use and abuse of antibiotics in clinical setting and in agriculture, added to the great ability of microorganisms to evolve, are the causes of the wide spread of isolates resistant to all major classes of current antibiotics. It is time for action in order to tackle antimicrobial-resistance (AMR), which can be considered a major threat to global health care and security. While we are waiting for new antimicrobial molecules and strategies, shorter-term approaches are needed to address the menace of AMR and preserve …

0301 basic medicineAntimicrobial-resistance antibioticsbusiness.industrymedicine.drug_class030106 microbiologyAntibioticsBiologySettore BIO/19 - Microbiologia GeneraleBioinformaticsApplied Microbiology and BiotechnologyBiochemistryMicrobiologyBiotechnology03 medical and health sciences0302 clinical medicineAntibiotic resistanceAction (philosophy)Agriculturemedicine030212 general & internal medicinebusinessBiotechnologyJournal of Microbial & Biochemical Technology
researchProduct

A Comparative Analysis of Aquatic and Polyethylene-Associated Antibiotic-Resistant Microbiota in the Mediterranean Sea

2021

Simple Summary In recent years, a growing interest has been devoted to the bacterial characterization of marine plastic debris. So far, a few publications have explored the composition of microbial communities on polyethylene (PE) waste items and the occurrence of antibiotic-resistant bacteria (ARB). The occurrence of ARB in natural matrices can contribute to the spread of antibiotic resistance genes (ARGs) among environmental bacteria. In this study, we compared the microbial composition and the presence of ARGs in water and PE fragments collected from a stream and the seawater in a coastal area of Northwestern Sicily. Our findings showed more ARGs on PE fragments than the corresponding wa…

0301 basic medicineAquatic environments030106 microbiologyPlastisphereBiologyIntegronArticleResistomeGeneral Biochemistry Genetics and Molecular BiologyIntegron03 medical and health sciencesAntibiotic resistanceMediterranean seaAntibiotic resistance genesFood scienceMicrobiomelcsh:QH301-705.5General Immunology and MicrobiologyAquatic ecosystemPlastisphereResistome030104 developmental biologylcsh:Biology (General)Antibiotic resistant bacteriaPolyethylenebiology.proteinSeawaterMicrobiomeGeneral Agricultural and Biological SciencesBiology
researchProduct

Doxorubicin anti-tumor mechanisms include Hsp60 post-translational modifications leading to the Hsp60/p53 complex dissociation and instauration of re…

2017

Hsp60 is a pro-carcinogenic chaperonin in certain tumor types by interfering with apoptosis and with tumor cell death. In these tumors, it is not known whether or not doxorubicin anti-tumor effects include a blockage of the pro-carcinogenic action of this protein. We used the human lung mucoepidermoid cell line NCI-H292 and different doses of doxorubicin to measure cell viability, cell cycle progression, cell senescence indicators, Hsp60 levels and its post-translational modifications as well as the release of the chaperonin into the extracellular environment. Cell viability was reduced in relation to doxorubicin dose and this was paralleled by the appearance of cell senescence markers. Con…

0301 basic medicineCancer ResearchLung NeoplasmsChaperoninsCellApoptosismedicine.disease_causeHistones0302 clinical medicineCellular SenescenceAntibiotics AntineoplasticAcetylationG2 Phase Cell Cycle Checkpointsmedicine.anatomical_structureOncology030220 oncology & carcinogenesisCell agingIntracellularProtein BindingSignal TransductionSenescenceCyclin-Dependent Kinase Inhibitor p21animal structuresCell Survivalchemical and pharmacologic phenomenaBiologycomplex mixturesMitochondrial ProteinsDoxorubicin Hsp60 Acetylation Ubiquitination p53 Replicative senescence03 medical and health sciencesDoxorubicin; Hsp60; p53; replicative senescence; post-translational modificationsCell Line TumormedicineHumansCell Proliferationdoxorubicin p53 Hsp60Dose-Response Relationship DrugCell growthfungiUbiquitinationChaperonin 60Molecular biology030104 developmental biologyAcetylationApoptosisDoxorubicinProteolysisCancer researchCarcinoma MucoepidermoidTumor Suppressor Protein p53CarcinogenesisProtein Processing Post-Translational
researchProduct

Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

2021

Simple Summary The immune checkpoint blockade (ICB), and concretely the blockade of the PD1/PDL1 axis, has opened up a new standard of treatment for non-small cell lung cancer (NSCLC). However, despite substantial advances in clinical care, many patients still remain refractory to these therapies. Biomarkers such as PD-L1 expression and tumor mutational burden have been associated with ICB efficacy, but the mechanisms underlying variable responses are not yet fully understood. Recently, the differential composition of the gut microbiota was studied as one of the variables accounting for interpatient heterogeneity in ICB responses. To better understand the potential role of the gut microbiot…

0301 basic medicineCancer Researchmedicine.drug_classmedicine.medical_treatmentAntibioticsGut floradigestive systemArticle03 medical and health sciences0302 clinical medicinemedicineLung cancerRC254-282non-small cell lung cancerbiologygut microbiotabusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunotherapyimmune checkpoint blockademedicine.diseasebiology.organism_classificationImmune checkpointBlockade030104 developmental biologyOncology030220 oncology & carcinogenesisImmunologyBiomarker (medicine)biomarkernext-generation sequencingimmunotherapybusinessProgressive disease
researchProduct

Resistance profiles and risk factors of resistant microorganisms in bacteraemia of abdominal origin

2017

Abstract Objective The presence of resistant microorganisms is a major cause of failure in initial empirical antimicrobial therapy. The objectives of this study are to determine the resistance profile of microorganisms that cause bacteraemia of abdominal origin and to identify whether the previous use of antibiotics and the place of acquisition of bacteraemia are risk factors associated with the presence of resistant organisms. Material and methods A clinical, observational, epidemiological, retrospective cohort study was conducted with all the adult patients admitted to a university hospital from 2011 to 2013. Antimicrobial resistance profiles were described and a 95% confidence interval c…

0301 basic medicineCarbapenembiologybusiness.industrymedicine.drug_class030106 microbiologyAntibioticsGeneral Medicinebacterial infections and mycosesmedicine.disease_causeAntimicrobialbiology.organism_classificationCandida parapsilosisMethicillin-resistant Staphylococcus aureusMicrobiology03 medical and health scienceschemistry.chemical_compoundAntibiotic resistancechemistryCandida kruseiLinezolidmedicinebusinessmedicine.drugRevista Española de Anestesiología y Reanimación (English Edition)
researchProduct

Active and Secretory IgA-Coated Bacterial Fractions Elucidate Dysbiosis in Clostridium difficile Infection

2016

C. difficile is a major enteric pathogen with worldwide distribution. Its expansion is associated with broad-spectrum antibiotics which disturb the normal gut microbiome. In this study, the DNA sequencing of highly active bacteria and bacteria opsonized by intestinal secretory immunoglobulin A (SIgA) separated from the whole bacterial community by FACS elucidated how the gut dysbiosis promotes C. difficile infection (CDI). Bacterial groups with inhibitory effects on C. difficile growth, such as Lactobacillales, were mostly inactive in the CDI patients. C. difficile was typical for the bacterial fraction opsonized by SIgA in patients with CDI, while Fusobacterium was characteristic for the S…

0301 basic medicineClostridium Cluster IVmedicine.drug_class030106 microbiologyAntibioticslcsh:QR1-502Microbiologylcsh:MicrobiologyantibioticsMicrobiologyHost-Microbe Biology03 medical and health sciencesClostridium difficile infectionmedicineMicrobiomeMolecular Biology16S rRNA gene sequencinghuman gut microbiomebiologyLactobacillalesdysbiosisClostridium difficilebiology.organism_classificationmedicine.diseaseQR1-502030104 developmental biologyBayesian networksFusobacteriumImmunologysecretory immunoglobulin ADysbiosisBacteriafluorescence-activated cell sortingResearch ArticlemSphere
researchProduct

Introduction: Novel hybrid combinations containing synthetic or antibiotic drugs with plant-derived phenolic or terpenoid compounds

2017

Abstract Background There is a paradigm shift in chemotherapy from mono-drug therapy towards multidrug combination regimens. Natural products from medicinal plants may play an important role for the design of novel combination therapy protocols. Hypothesis We introduce the novel term “hybrid combination” for the therapeutic combination of chemically defined plant-derived constituents (e.g. phenolic or terpenoid compounds with synthetic or antibiotic drugs to increase pharmacological activity and simultaneously toxic side effects. Study design Several literature databases were screened on the combination of phenolic/terpenoid compounds with synthetic/antibiotic drugs. Results Phenolic compou…

0301 basic medicineCombination therapymedicine.drug_classAntibioticsHerb-Drug InteractionsPharmaceutical ScienceDrug resistancePharmacologyAntioxidants03 medical and health sciencesPhenolsNetwork pharmacologyDrug DiscoverymedicineHumansOrganic chemistryMedicinal plantsAntibiotic DrugsPharmacologyBiological ProductsPlants MedicinalPlant ExtractsTerpenesChemistryBiological activityTerpenoidAnti-Bacterial Agents030104 developmental biologyComplementary and alternative medicineMolecular MedicineDrug Therapy CombinationPhytomedicine
researchProduct